|
|
| | Scopolamine butylbromide Basic information |
| | Scopolamine butylbromide Chemical Properties |
| Melting point | 142-1440C | | alpha | D20 -20.8° (c = 3 in water) | | storage temp. | 2-8°C | | solubility | H2O: 50 mg/mL | | form | powder | | color | white | | optical activity | [α]25/D 20.8°, c = 3 in H2O(lit.) | | CAS DataBase Reference | 149-64-4(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | RTECS | YM3500000 | | Toxicity | LD50 in mice (mg/kg): 15.6 i.v.; 74 i.p.; 570 s.c.; 3000 orally (Stockhaus, Wick) |
| | Scopolamine butylbromide Usage And Synthesis |
| Chemical Properties | Crystalline Solid | | Originator | Butylscopolamine,China Pharm | | Uses | (?)-Scopolamine N-butyl bromide was used as standard in designing a procedure for quantification of compounds using CE-MS.8 | | Uses | Anticholinergic. Antispasmodic | | Definition | ChEBI: Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic bromide salt and a quaternary ammonium salt. It contains a butylscopolamine. | | Manufacturing Process | 1300 g of scopolamine base and 350 g of n-butylbromide in 600 ml
acetonitrile is heated at 65°C for 160 hours. The oil obtained is dissolved in
methanol. The solution is cooled and crystalline scopolamine N-n-butylbromide
is filtered. After recrystallization from methanol was obtained scopolamine N-n-butylbromide with melting point 142-144°C and [α]d
20 = -20.5° (3%
solution in water); yield 65%. | | Therapeutic Function | Anticholinergic, Spasmolytic, Antitussive | | Biochem/physiol Actions | Competitive muscarinic acetylcholine receptor antagonist; antispasmodic. | | Clinical Use | Symptomatic relief of gastrointestinal or genitourinary
disorders due to smooth muscle spasm
Bowel colic
Excessive respiratory secretions | | target | AChR | | Metabolism | The main metabolic pathway is the hydrolytic cleavage
of the ester bond. Orally administered hyoscine
butylbromide is excreted in the faeces and in the
urine. Studies in man show that 2-5% of radioactive
doses is eliminated renally after oral, and 0.7-1.6%
after rectal administration. Approximately 90% of
recovered radioactivity can be found in the faeces after
oral administration. The urinary excretion of hyoscine
butylbromide is less than 0.1% of the dose. The
metabolites excreted via the renal route bind poorly to muscarinic receptors and are therefore not considered to
contribute to the effect of the hyoscine butylbromide. |
| | Scopolamine butylbromide Preparation Products And Raw materials |
|